For the second quarter NeoGenomics reported earnings of 2 cent a share, in line with the Capital IQ Consensus Estimate. Revenue grew 32.7% from the year-ago quarter to $20.7 million, above analysts' estimates of $20.12 million.
Looking to the third quarter NeoGenomics expects earnings of between a loss of 1 cent and a 1 cent a share while analysts expect the company to break even for the quarter. The company expects revenue of $22 million to $23.5 million in the third quarter, about analysts' expectations of $21.6 million.
Must read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. NEO data by YCharts STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts